Digitalisation

#Biotech #Digitalisation #Drug development #Regulatory

Why late-stage pharma R&D processes need a rethink 

Across pharma regulatory affairs, quality and pharmacovigilance/drug safety functions, process rigour is wedded tightly to SOPs. But these snapshot definitions of processes do not, of themselves, foster efficiency. In many cases, there has been a loss of sight of the deliverables. Here, Tobias Hitziger, Management Consultant at MAIN5… Read More

#Exclusive Content #Regulatory

#AI / data analytics / healthtech / informatics #Alzheimer's #Automation #Biomarkers #Data automation #Data management #Digital biomarkers #Digitalisation #Drug development #Drug discovery #Genetics / genomics #Mass spectrometry / NMR #Neurodegenerative disorders #Neuroscience

New podcast: The far-reaching impact of drug discovery technology

This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More

#News

#Biopharma #Digitalisation #Drug development #Drug discovery

How “digitally mature” is your pharma company? 

By Craig Williamson, Lead Platform Product Manager, Integrations Strategy at IDBS.   The biopharma industry is changing. Companies with mature digital approaches are achieving operational efficiencies and breakthroughs in R&D. Companies that don’t risk being left behind.   Digital maturity is not just about… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automation / robotics #Digitalisation #Lab technology

How digital innovation is helping therapeutics to get to market faster

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and… Read More

#Exclusive Content

Regulatory concept
#AI / data analytics / healthtech / informatics #Digitalisation #Drug development #Regulatory

Reflections on life science’s regulatory environment  

In this article, Amplexor asks some of the company’s closest industry partners and BE THE EXPERT event speakers for their views on the biggest developments in the Life Sciences Regulatory sphere over the last 12 months – and explore some of the most prominent themes and priorities seen throughout… Read More

#Exclusive Content

Digital bioprocessing
#Bioprocessing #Culture Biosciences #Cytiva #Digitalisation #In Silico Biology

Collaboration seeks to advance upstream bioprocessing 

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities.   Together, the companies aim to bring new bioprocess solutions to customers that use digitaliation, in-silico approaches, and virtual monitoring and control of experiments. … Read More

#News

#Contract Research Organisations (CROs) #Digitalisation #Proscia #Research #Therapeutics

Key findings from life sciences digital pathology adoption survey 

Nearly three-fourths of life sciences organisations surveyed have invested in digital pathology to advance drug research and development (R&D), according to new research commissioned by Proscia. Over half of these organisations (53%) still center their operations around legacy software systems primarily for basic image viewing despite growing adoption of… Read More

#Editor's Choice #News

#Autolomous #Cell and gene therapy #Cell and Gene Therapy Catapult #Digitalisation #Funding

CGT grant funds implementation and digitisation of PAT  

Autolomous, a developer of critical manufacturing management systems for cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of CGTs, have been awarded a joint £1.2 million grant by UK Research and Innovation (UKRI),… Read More

#News

FDA
#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Digitalisation #FDA

FDA announces additional steps to modernise clinical trials

The US Food and Drug Administration has published draft guidance with updated recommendations for good clinical practices (GCPs) to modernise the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials. The draft guidance is… Read More

#Editor's Choice #News #Regulatory

Future Labs Live
#AI / data analytics / healthtech / informatics #Digitalisation #Events #Future Labs Live #Lab automation #Lab of the future

What will the lab of the future look like?

What is Future Labs Live? Future Labs Live is becoming the world’s most important ‘future lab’ congress. We are breaking out of silos to enable individuals to meet, talk, and debate across function, industry, and geography. We are returning to Basel, the pharma hub of Europe, from May 31 – June 2,… Read More

#News

#Clinical trials #Decentralised clinical trials #Digitalisation

Cambridge Cognition set to become key player in virtual clinical trials 

Cambridge Cognition has entered into an agreement to acquire eClinicalHealth Ltd (eCH), a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.   Catalysed by the pandemic, the overall virtual clinical trials market has grown rapidly… Read More

#News

#Biopharma #Digitalisation #Regulatory

The next steps for biopharma regulations

Following a decade of solid groundwork to modernise regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape – to transform process management; improve data exchange with the enterprise at large; revisit organisational structures… Read More

#Exclusive Content #Regulatory #Trends & Analysis